“…Table 1 lists 30 experimental studies [15, which utilized the pig model to analyze the cardiopulmonary adverse effects of different nanoparticles (NPs) or other agents. Some of these studies highlighted the concordance of HSR symptoms in pigs and hypersensitive patients [25][26][27][28][29]32,33,[46][47][48], others addressed the mechanism of HSRs [15,[21][22][23][24][25][26][27][28][29][30][31][32][33]36,[41][42][43][44][45][46][47], and yet others focused on the prevention of HSRs by pharmacological intervention [15], or by optimizing the structure [24,44] or administration protocol [24,37,48] of NPs. Importantly, many of these studies were initiated mainly for preclinical safety evaluation of nanomedicines [15,22,23,30,31,35,…”